这家总部位于英国剑桥的制药公司表示，Gefurulimab在第26周时显示出比安慰剂的改善，早在第一周就观察到具有临床意义的改善，并持续到第26周。全身型重症肌无力是一种罕见的自身免疫性疾病，其特征是肌肉功能丧失和严重的肌肉无力。

【阿斯利康】周四宣布，其在研抑制剂Gefurulimab的III期临床试验在重症肌无力患者的日常生活活动方面达到了主要终点。 这家总部位于英国剑桥的制药公司表示，与安慰剂相比，Gefurulimab在第26周时显示出改善，早在第一周就观察到具有临床意义的改善，并持续到第26周。全身型重症肌无力是一种罕见的自身免疫性疾病，其特征是肌肉功能丧失和严重的肌肉无力。 阿斯利康罕见病部门Alexion的研发 ...

Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.

AstraZeneca announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia gravis, marking a significant advancement in their product line. Last week, the ...

Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from a global, randomized, double-blind, placebo-controlled phase III trial with ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...